bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Update

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the recipient of a significant growth in short interest in September. As of September 30th, there was short interest totalling 396,200 shares, a growth of 18.0% from the September 15th total of 335,900 shares. Approximately 5.3% of the company’s stock are short sold. Based on an average daily volume of 110,000 shares, the short-interest ratio is presently 3.6 days.

bioAffinity Technologies Stock Performance

NASDAQ:BIAF traded down $0.04 during trading hours on Monday, reaching $1.87. 42,918 shares of the company’s stock were exchanged, compared to its average volume of 132,899. The firm has a market capitalization of $21.80 million, a price-to-earnings ratio of -2.05 and a beta of 2.92. The company has a 50-day moving average of $1.76 and a 200 day moving average of $2.13. The company has a quick ratio of 1.14, a current ratio of 1.15 and a debt-to-equity ratio of 0.19. bioAffinity Technologies has a 1-year low of $1.15 and a 1-year high of $3.62.

bioAffinity Technologies (NASDAQ:BIAF) last released its earnings results on Wednesday, August 14th. The company reported ($0.19) EPS for the quarter. bioAffinity Technologies had a negative return on equity of 172.06% and a negative net margin of 120.76%. The firm had revenue of $2.40 million during the quarter.

Wall Street Analyst Weigh In

Separately, Maxim Group started coverage on shares of bioAffinity Technologies in a report on Tuesday, July 23rd. They set a “buy” rating and a $6.00 price target for the company.

Institutional Trading of bioAffinity Technologies

A hedge fund recently bought a new stake in bioAffinity Technologies stock. Ground Swell Capital LLC bought a new stake in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF) in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 22,864 shares of the company’s stock, valued at approximately $49,000. Ground Swell Capital LLC owned approximately 0.20% of bioAffinity Technologies at the end of the most recent quarter. Institutional investors own 1.64% of the company’s stock.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.